Company Overview and News


Add PBYI
to your dashboard

Headline News

Corporate News Blog - Puma Biotechnology’s 5-Year Analysis of Phase-III ExteNET Study Gets Published in ‘The Lancet Oncology’

2017-11-16 accesswire
LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Puma Biotechnology, Inc. (NASDAQ: PBYI), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=PBYI. The biopharmaceutical Company, which focuses on the development and commercialization of innovative products to enhance cancer care, announced on November 13, 2017, that its previously presented results from the ExteNET Phase-III clinical trial for Neratinib in patients with early stage HER2-positive breast cancer got published in the online journal ‘The Lancet Oncology'. (19-0)

Puma Biotechnology, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-13 seekingalpha
The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2017 Q3 earnings call. (11-0)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

2017-11-10 zacks
Puma Biotechnology, Inc. (PBYI - Free Report) reported a loss of $2.07 in the third quarter of 2017, much narrower than the Zacks Consensus Estimate of a loss of $3.46. The company had reported a loss of $2.02 in the third quarter of 2016. (29-0)

Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
At this time all participants are in a listen-only-mode. After the speaker's formal remarks, there will be a question-and-answer session. [Operator Instructions] As a reminder this call is being recorded. I would now like to turn the conference over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin your conference. (11-0)

Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?

2017-11-08 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Puma Biotechnology Inc (PBYI - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Puma Biotechnology is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. (29-0)

Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

2017-11-08 zacks
The third-quarter reporting cycle is drawing to a close. Quarterly results have been strong. Overall, the beat percentage is in line with the recent quarters but growth rates have been particularly impressive. Also, the estimate revision trend for Q4 has been mostly favorable. (135-0)

Puma Biotechnology Continues To Thrive Despite European Debacle

2017-11-07 seekingalpha
Puma Biotechnology, Inc. (NASDAQ:PBYI) got approval for neritinib, or Nerlynx, a tyrosine kinase inhibitor that blocks HER1, HER2, HER3 and HER4, and is approved for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in adult patients who have been previously treated with a regimen that includes the drug trastuzumab. This is a $13bn market (2023 estimates), and while Herceptin made $5bn last year in annual sales, other drugs have not been so successful. (11-0)

Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

2017-11-07 zacks
We expect Puma Biotechnology, Inc. (PBYI - Free Report) to beat estimates when it reports third-quarter 2017 results on Nov 9 after market close. (71-0)

5 Biotech Stocks Well Poised to Surpass Expectations in Q3

2017-11-07 zacks
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results. The majority of players within the medical space have already reported their performance. Per the latest Earnings Trends, total earnings for the medical sector are up 6.5% from the same period last year on 4.6% higher revenues. This year, biotech stocks bounced back strongly after the drug pricing issue affected last year’s performance. (27-0)

36 Stocks For November 2017

2017-11-06 seekingalpha
Every month, we construct a theoretical long/short portfolio of stocks that demonstrates solid relative value with potential for ongoing cash flow growth and ROIC expansion. (703-1)

BRIEF-Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance

2017-11-02 reuters
* Puma Biotechnology - ‍proceeds from financing will be used to continue to support Nerlynx commercial activities, ongoing research with neratinib ​ Source text for Eikon: Further company coverage: (11-1)

Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi

2017-10-10 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)

CUSIP: 74587V107